Dartmouth College

Dartmouth Digital Commons
Dartmouth Scholarship

Faculty Work

12-1-2022

I am hiQ—a novel pair of accuracy indices for imputed genotypes
Albert Rosenberger
Universitätsmedizin Göttingen

Viola Tozzi
Universitätsmedizin Göttingen

Heike Bickeböller
Universitätsmedizin Göttingen

Rayjean J. Hung
University of Toronto

David C. Christiani
Harvard T.H. Chan School of Public Health

See next page for additional authors
Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa

Dartmouth Digital Commons Citation
Rosenberger, Albert; Tozzi, Viola; Bickeböller, Heike; Hung, Rayjean J.; Christiani, David C.; Caporaso, Neil
E.; Liu, Geoffrey; Bojesen, Stig E.; Le Marchand, Loic; Albanes, Demetrios; Aldrich, Melinda C.; Tardon,
Adonina; Fernández-Tardón, Guillermo; Rennert, Gad; Field, John K.; Davies, Mike; Liloglou, Triantafillos;
Kiemeney, Lambertus A.; Lazarus, Philip; Haugen, Aage; Zienolddiny, Shanbeh; Lam, Stephen; Schabath,
Matthew B.; Andrew, Angeline S.; Duell, Eric J.; Arnold, Susanne M.; Brunnström, Hans; Melander, Olle; and
Goodman, Gary E., "I am hiQ—a novel pair of accuracy indices for imputed genotypes" (2022). Dartmouth
Scholarship. 4280.
https://digitalcommons.dartmouth.edu/facoa/4280

This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has
been accepted for inclusion in Dartmouth Scholarship by an authorized administrator of Dartmouth Digital
Commons. For more information, please contact dartmouthdigitalcommons@groups.dartmouth.edu.

Authors
Albert Rosenberger, Viola Tozzi, Heike Bickeböller, Rayjean J. Hung, David C. Christiani, Neil E. Caporaso,
Geoffrey Liu, Stig E. Bojesen, Loic Le Marchand, Demetrios Albanes, Melinda C. Aldrich, Adonina Tardon,
Guillermo Fernández-Tardón, Gad Rennert, John K. Field, Mike Davies, Triantafillos Liloglou, Lambertus A.
Kiemeney, Philip Lazarus, Aage Haugen, Shanbeh Zienolddiny, Stephen Lam, Matthew B. Schabath,
Angeline S. Andrew, Eric J. Duell, Susanne M. Arnold, Hans Brunnström, Olle Melander, and Gary E.
Goodman

This article is available at Dartmouth Digital Commons: https://digitalcommons.dartmouth.edu/facoa/4280

(2022) 23:50
Rosenberger et al. BMC Bioinformatics
https://doi.org/10.1186/s12859-022-04568-3

RESEARCH

BMC Bioinformatics
Open Access

Iam hiQ—a novel pair of accuracy indices
for imputed genotypes
Albert Rosenberger1,2* , Viola Tozzi1 and Heike Bickeböller1 on behalf of the INTEGRAL-ILCCO consortium

*Correspondence:
arosenb@gwdg.de
2
Institut für Genetische
Epidemiologie,
Universitätsmedizin
Göttingen, Humboldtallee
32, 37073 Göttingen,
Germany
Full list of author information
is available at the end of the
article

Abstract
Background: Imputation of untyped markers is a standard tool in genome-wide
association studies to close the gap between directly genotyped and other known
DNA variants. However, high accuracy with which genotypes are imputed is fundamental. Several accuracy measures have been proposed and some are implemented in
imputation software, unfortunately diversely across platforms. In the present paper, we
introduce Iam hiQ, an independent pair of accuracy measures that can be applied to
dosage files, the output of all imputation software. Iam (imputation accuracy measure) quantifies the average amount of individual-specific versus population-specific
genotype information in a linear manner. hiQ (heterogeneity in quantities of dosages)
addresses the inter-individual heterogeneity between dosages of a marker across the
sample at hand.
Results: Applying both measures to a large case–control sample of the International
Lung Cancer Consortium (ILCCO), comprising 27,065 individuals, we found meaningful
thresholds for Iam and hiQ suitable to classify markers of poor accuracy. We demonstrate how Manhattan-like plots and moving averages of Iam and hiQ can be useful to
identify regions enriched with less accurate imputed markers, whereas these regions
would by missed when applying the accuracy measure info (implemented in IMPUTE2).
Conclusion: We recommend using Iam hiQ additional to other accuracy scores for
variant filtering before stepping into the analysis of imputed GWAS data.
Keywords: GWAS, High-throughput genotyping, Genotype imputation, Accuracy
measures

Background
To date information of more than 660 million reference single nucleotide polymorphisms (refSNPs) and 5.9 million regions with structural variation (SV) on the human
DNA are known and stored in the publicly available databases, like dbSNP [1]. To
identify those genetic variants, that are associated with common human diseases,
genome-wide association studies (GWAS) can be conducted. Usually, commercial single
nucleotide polymorphism (SNP) microarrays are used to carry out genotyping of DNA
samples for these studies. There are two predominant companies for high throughput
genotyping arrays, Thermo Fisher Scientific Inc., Santa Clara, CA (Affymetrix™) and
© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits
use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third
party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or
exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://
creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publi
cdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
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Illumina Inc., San Diego, CA. The underlying chemistry differs but both array types can
be used to ascertain genotypes in a similar fashion [2]. In contrast to the more expensive and error prone new generation sequencing technologies, the number of genotyped
variants ranges from 300,000 to 4 million. Array-based markers are supposed to tag the
genomic region in their vicinity, but represent only a small proportion of all known DNA
variants. Furthermore, these variants are not a random selection but have been chosen
according to criteria such as minor allele frequency (MAF), location in exons or blocks
of linkage disequilibrium or putative associations with certain disease.
Imputation methods and strategies have been developed and are now a standard tool
in GWAS to close the gap between genotyped and existing DNA variants [3–5]. These
methods transfer information of DNA structure from one or several reference panels
with high marker density (e.g. 1000 Genomes Project phase 3 [6] or Haplotype Reference
Consortium (HRC) [7]) to the genotyped study samples [4]. Most imputation methods
estimate a-posteriori genotype probabilities (referred to as dosages, ranging from 0 to
1) for each untyped variant and each individual in the sample of interest. The resulting
increase of variant density in the study sample improves the genomic coverage and can
increase the power to identify genomic variants associated with a trait [8]. Imputation
further has the potential that an identified associated marker is located closer to a true
risk locus; it facilitates fine mapping of causal variants and is essential for meta-analyses
of GWAS, particularly when different genotyping arrays have been used for multiple
studies [9]. However, imputation requires advanced statistical methods for data analysis
and may introduce extra uncertainty in interpreting findings. Further, only DNA variants that have previously been genotyped in the used reference panel can be imputed [4,
10].
Imputation methods based on linkage disequilibrium (LD) information (e.g. fastPHASE [11]; MaCH [12, 13]; Beagle [14]; IMPUTE2 [15]) and are suitable for samples
of independent individuals, as in case–control studies. Other methods use pedigree and
linkage information (e.g. F-Impute [16]; α-Impute [3, 17]), and are therefore suitable for
related individuals.
Known accuracy measures

It is important to evaluate the quality of imputation, e.g. to exclude poorly imputed variants from statistical analysis. Several quality indices have been developed and are routinely applied [4, 5, 18]. These comprise inter alia the squared correlation r2 between the
true and imputed dose of an allele across all imputed samples (MaCH r2, Minimac or
Beagle r2) or IMPUTE2’s info.
All r2 measures can be derived from a-posteriori allele probabilities without knowledge of the true allele dose, but only if the allele probabilities are well calibrated and
MAF is not too low. The power of an allelic test with N samples and imputed alleles is
approximately equal to the power of the same test with r2N samples and known alleles,
in case of a binary trait. Differences among the known r2 measures are discussed elsewhere [4]. The commonly used info is defined as the proportion of statistical information on the population allele frequency in the imputed genotypes, relative to “known”
genotypes [5]. If the Hardy–Weinberg disequilibrium (HWE) holds, info equalizes to
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Minimacs r2. Hence, r2-based measures and info are directly related to the power of statistical test of a marker x trait association.
In general, both metrics have preferable characteristics if the a-posteriori genotype
probabilities (dosages) are accurately calculated [18]. However, multiple factors can
affect imputation accuracy, e.g. sample size, sequencing coverage and haplotype accuracy of the references panel(s), density of the genotyping array, allele frequency and
poor LD between genotyped and imputed variants [4]. One can calculate these accuracy
measures from dosage files. However, the standard outputs of common imputation programs (e.g. Beagle or IMPUTE2) contain different metrics. Hence, choosing an imputation program binds the user to the metrics provided, although the SNPTEST program
offers the option of calculating a measure similar to that of info [19].
We propose a new pair of metrics to depict additional aspects of imputation accuracy
also calculable from dosage files. First, we aim to quantify the amount of individual-specific versus population-specific genotype information in the imputed genotypes. Second,
we aim to assess the heterogeneity between dosages of a marker across the sample at
hand. Both measures can be used to identify markers or regions in which populationspecific genetic information conceal individual-specific information and are therefore less informative for e.g. association testing. These new metrics are not intended
as a competitor to established scores, but are intended to support the making of wellfounded decisions in SNP filtering of imputed markers prior to an analysis or in interpretation of results after an analysis.
We calculated this pair of accuracy measures on a series of 27,065 cases and controls
gathered by the International Lung Cancer Consortium (ILCCO) to find meaningful
thresholds for marker exclusion and compared it with info, because all of the ILCCO
samples had previously been imputed with IMPUTE2 applied to a standard 1000
Genomes referent panel. Further, we contrasted the usability of the new measures to info
in some simulated data.

Results
Comparison of Iam and hiQ

When applying the novel indices Iam hiQ (as defined in the section Novel accuracy
measures) to 517,482 SNPs types with the OncoArray, only a small portion (n = 40,678,
4‰) can be considered as imputed without doubt (Iam = 1 and hiQ = 1). For the majority of SNPs a value between 0.95 and < 1 was assigned for hiQ (9,760,392, ~ 94%), while
only 30% (n = 3,243,272 markers) achieved such a large value with respect to Iam. It is
worth to mention, that we assigned a reduced value for Iam (from 0.4 to 0.75) to about
as many SNPs (n = 3,491,596, 33%). More details are given in Additional file 1: Table S1.
Both components of Iam hiQ, are contrasted in a bubble plot (Fig. 1). The oversized
grey bubble in the top right corner represents the vast majority of almost fully-informative markers with Iam ≥ 0.99 and hiQ ≥ 0.99. It can easily be seen that the remaining
small minority of not fully accurately imputed markers take advantage of the whole theoretical range for Iam (even negative values). In contrast, hiQ always exceeds 0.4 in the
sample at hand, but seems to be sensitive in markers with low values for Iam, whereas
lower values of hiQ are only assigned to common markers.
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Fig. 1 Iam by hiQ. Main panel: all markers by Iam vs. hiQ; blue dots: variants with info < 0.5; red dots: variants
with 0.5 ≤ info < 0.8; 8; green dots: variants with info ≥ 0.8; dotted line: robust 99.9999999% bivariate normal
random interval (assuming a two-dimensional normal distribution). The oversized grey bubble in the top
right corner represents the vast majority of almost fully-informative markers with Iam ≥ 0.99 and hiQ ≥ 0.99;
inserted panel: like main panel, but marker are divided according to the minor allele frequency

Defining thresholds for marker filtering

In order to exclude less accurately imputed variants from further analysis, one needs
to define a meaningful and applicable threshold for any accuracy index. For the measure info threshold values like 0.8 or 0.3 have been proposed, but without sound justification [5, 20, 21]. It was even proposed to lower the threshold for info in very large
samples, as those of the UK Biobank, and still maintain a good ability to detect associations [22].
We applied robust regression (PROG ROBUSTREG of SAS 9.4; cut-off-α = 10–6 for
leverage points, cut-off-multiplier = 5 for outliers[23]) to estimate the expected value
of Iam and hiQ and their variance–covariance matrix, assuming a hidden two-dimensional normal distribution (ignoring the upper bounds of the indices). Based on this
we derived the 99.9999999% (1–10−9) random region (dashed line in Fig. 1) to define,
very conservative and data driven, lower bounds for the two indices, limiting the
probability of a false-exclusion to ~ 1/(100∙10,439,017) (one hundredth under Bonferroni correction assuming independent markers). The robust mean for Iam was 0.7409
that for hiQ was 0.9885. Restricted to common markers (MAF ≥ 0.1) we achieved similar mean values (Iam: 0.8101, hiQ: 0.9894). The lower bounds of the random region
of hiQ were 0.9627 for all markers and 0.9673 for common markers, which is almost
identical. In contrast, the lower bounds of the random region of Iam were 0.2553 for
all markers and 0.4657 for common markers, demonstrating the influence of MAF,
via HWE, on Iam. We decided to use the study specific thresholds of 0.47 for Iam
and 0.97 for hiQ to further classify markers of poor accuracy. Because Iam ranges linearly from population informative dosages to fully individual informative dosages, the
threshold of ~ 0.5 indicates markers with less than ~ 50% individual-specific genotype
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information (in average across all samples). Such an intuitive interpretation cannot be
given for hiQ.
For the majority of 9,094,772 (87.2%) variants, sufficient imputation accuracy was
achieved, according to our defined thresholds (see Table 1). Limiting the markers to
those with 0.5 < info ≤ 0.8 and info ≥ 0.8, this fraction increases to 95.1% or 99.9%,
respectively. In very rare genetic variants (MAF < 1%) the fraction drops to 76.5%. In
contrast, only 0.6% of variants meet neither the Iam nor the hiQ criteria. Interestingly, 1,214,620 variants (11.7%) missed only the Iam criteria. The fraction was larger
in very rare variants (23.2%) and in variants with info < 0.5 (58.5%), while it was moderate in variants with 0.5 < info ≤ 0.8 (2.5%).
Identifying markers and regions of low accuracy

Figure 2 presents the accuracy of imputed markers according to Iam hiQ in a Manhattan-like plot, with Iam given in the lower part (blue) and hiQ given in the upper part
(red). This plot contains all 10,427,599 SNPs. Regions with massively less accurate
imputation can easily be identified, especially by hiQ (red needles). This is for instant
the case close to the centromere of chromosomes 1, 2 and 9 (accuracy by chromosome 1 is presented in Additional file 1: Figure S1). However, variants with Iam or
hiQ below the defined thresholds can be found in many regions across the whole
genome. Massively less accurate imputation can be found upstream the centromere,
less distinct downstream the centromere and close to the telomeres, as well as around
position 50K (blue icicle). Nevertheless, it is still hard to visually find regions that are
enriched with less accurately imputed markers.
To identify more genomic regions prone to host inaccurate markers we calculated
the exponentially weighted moving averages (ewma) of Iam and hiQ (PROC EXPAND
of SAS 9.4; smoothing factor 0.1) [23]. We consider variants with an ewma < threshold (0.47 for Iam and 0.97 for hiQ) as belonging to a “hot region” and variants with an
ewma < threshold/2 (0.23 for Iam and 0.48 for hiQ) as belonging to a “very hot region”.
Across the whole genome, we were able to identify 4,603 “hot regions” and 171 “very
hot regions” according to IamHWE, as well as 2,899 “hot regions” according to hiQ. These
regions partially overlap or are interconnected. “Hot” and “very hot” Iam-regions contain in total 85,790 variants, only about 8‰ of all variants. “Hot” hiQ-regions contain
in total 53,590 variants, only about 5‰ of all variants. However, about 1 out of 3 “hot”
or “very hot” regions is very small and contains only one variant. In contrast, 10% of
the “hot” Iam-regions and about 20% of either the “very hot” Iam- or the “hot” hiQregions contain more than 20 variants (see Additional file 1: Tables S2–S4). Some of
these regions on chromosome 1 are indicated by flames in Fig. 3.
Comparing Iam hiQ with info and certainty

The missing rate for info was about 18% and 0.6% for certainty, in the data set at hand.
Iam and hiQ could be determined for all markers (see Additional file 1: Table S5). The
correlation between Iam and info was largest (r2 = 0.944), indicating that both represent
comparable information on accuracy. hiQ and certainty correlate only moderate among
themselves as do the other measures (r2 < 0.5) (see Table 2). However, only every second
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Table 1 Classification of markers by IamHWE and hiQ
hiQ

IamHWE
< 0.47
%a

N

≥ 0.47
N

%a

All markers

Quality defined by info
Low quality: info < 0.8
High quality: info ≥ 0.8
Minor allele frequency (MAF)
< 1%

< 0.97

59,077

≥ 0.97

1,214,620

< 0.97

59,077

≥ 0.97

1,214,612

≥ 0.97

8

< 0.97

0.6%
11.7%
1.2%
23.8%
–

< 0.97

15,366

≥ 0.97

1,210,505
13,448

< 0.1%
0.3%
23.2%

59,130
9,094,772
58,592

0.6%
87.2%
1.1%

3,777,566

73.9%

538

< 0.1%

5,317,206

99.9%

136

< 0.1%

4,000,616

< 0.97

5% to < 10%

< 0.97

10% to < 30%

< 0.97

30% to 50%

< 0.97

721,679

98.1%

> 50%

< 0.97

8,532

0.9%

11,371

1.1%

≥ 0.97

1,520

0.2%

972,504

97.8%

≥ 0.97

≥ 0.97

0.9%

12,742

2,317

0.2%

1,472,328

4,007

0.6%

12,117

76.5%

1% to < 5%

7
8,441

≥ 0.97

10
9,283

≥ 0.97

261

< 0.1%
0.6%
< 0.1%
1.3%
< 0.1%

0.8%
98.1%
1.8%

638,931

97.5%

18,576

1.4%

1,288,714
4,188

97.9%
0.6%

Thresholds for IamHWE (0.47) and hiQ (0.97) were defined according to a robust 99.9999999% bivariate normal random
interval (assuming a two-dimensional normal distribution)
Proportion within tabulated subgroup of markers

(negative) 1-Iam* / 1-hiQ

a

hiQ cutoff

Iam cutoff

position
Fig. 2 Manhattan-like-plot: Iam hiQ. Upper panel: hiQ (low Q.: hiQ = 0; high Q.: hiQ = 1; Thresholds
hiQ (cutoff = 0.97); lower panel: IamHWE (low Q.: IamHWE = 0; high Q.: IamHWE = 1; Thresholds Iam cutoff = 0.47):
Thresholds were defined according a robust 99.9999999% bivariate normal random interval (assuming a
two-dimensional normal distribution)
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fully-informative SNP (Iam = 1 and hiQ = 1) was assigned a value ≥ 0.8 for info (see
Additional file 1: Table S1, red shaded points in Fig. 1), whereas this was the case for less
than 2‰ of variants with reduced Iam (0.4 to 0.75). This means that Iam and info nevertheless carry different information on imputation accuracy.
Figures for a visual comparison of Iam and info are included in the Additional file 1:
Figures S2 and S3. These clearly show that info is less suitable for mapping regions
enriched with less accurately imputed genotypes, genome-wide and chromosome-wide.

Usability
We also investigated the usability of the proposed indices in contrast to info by simulation. Usability was considered in terms of discrimination between sufficient and insufficient imputation, rather than in terms of validity of imputation because validity is a
characteristic of the imputation routine (e.g. IMPUTE2).
Eight scenarios consisting of two common genotyped tagSNPs flanking one intermediate marker for imputation were defined, differing from each other by the underlying haplotype structure, MAF and LD-patterns were defined. Two scenarios each form
a pair (a scene), consisting of a scenario in which the missing marker can be imputed
sufficiently/better and one scenario in which the missing marker can be imputed insufficiently/worse. Imputation was performed on 100 randomly drawn samples for each
scenario, and accuracy measures were calculated. The ability of an index to discriminate
a sufficient from an insufficient scenario (usability) was visually inspected plotting comparative receiver operation curves (one ROC per index) for each scene, and quantified
as area under der curve (AUCs) of ROCs. Details on the simulation and the results are
given in the Additional file 1.

Fig. 3 Manhattan-like-plot: Iam hiQ: chromosome 1. Upper panel: hiQ (low Q.: hiQ = 0; high Q.: hiQ = 1;
Thresholds hiQ (cutoff = 0.97); lower panel: IamHWE (low Q.: IamHWE = 0; high Q.: IamHWE = 1; Thresholds
Iam cutoff = 0.47): Thresholds were defined according a robust 99.9999999% bivariate normal random
interval (assuming a two-dimensional normal distribution); red flames indicate “very hot” regions; orange
flames indicate “hot” regions
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Table 2 Correlation between accuracy measures
IamHWE

hiQ

info

certainty

IamHWE

–

0.684

0.944

0.484

hiQ

0.405

–

0.367

0.156

info

0.976

0.686

–

0.050

certainty

0.305

0.335

0.051

–

Right upper triangle: Pearson’s correlation coefficient, left lower triangle: Spearman’ rank correlation coefficient

Info and Iam appear to be comparable usable in terms of discrimination between sufficient and insufficient imputation for common SNPs. However, hiQ seems to be superior
when MAF of the imputed marker is low.

Suggestion on how to use Iam hiQ
For general use, a threshold of 0.5 for Iam and 0.9 for hiQ seems reasonable to identify
markers with low accuracy. However, we do not claim that this recommendation to generally optimal. All variants with values for Iam and e.g. info below the threshold value,
as well as all variants with MAF < 1% and a hiQ below the threshold value should be
excluded from a data analysis in order to ensure that all aspects of the imputation quality are met. This pre-analysis marker filtering can be extended to all variants in “hot” or
“very hot” regions. If association results cannot be replicated across several studies, a
low value of Iam indicates a reduced individual-specific information content, even if, for
example, info and hiQ imply sufficient power and genotype heterogeneity.
Discussion
Imputation is a cost-effective tool for GWAS to fill gaps of non-genotyped variants
instead of whole-genome sequencing for all recruited individuals, since global coverage
in genomic information of available arrays with less than 1 million SNPs not exceeds
25% [10, 24]. However, imputation accuracy matters. Several accuracy measures have
been proposed and implemented in imputation software, unfortunately diverse across
platforms. Das et al. [4] favour r2, the squared correlation between true and imputed
allele dose, because it is tightly related to the power of an allelic test. However, they also
emphasized the importance of adequate imputed samples for the r 2accuracy.
We introduce Iam hiQ, an independent and complementary pair of accuracy measures. Other than e.g. r2, Iam quantifies the amount of individual-specific versus population-specific genotype information in a linear manner for each individual before
averaging, while hiQ addresses the inter-individual heterogeneity of dosages for a
marker across the sample at hand. These new measures are not intended to compete
with established scores, but should complement them. We derived meaningful, but
study specific thresholds for variant filtering applying Iam hiQ to a large case–control
sample at hand. We showed how regions enriched with less accurately imputed genotypes can be identified (computationally and visually), and finally compared Iam hiQ to
info, as provided by IMPUTE2. Iam hiQ is simple to interpret: Iamchance of 0 indicates a
complete loss of genomic information for a variant. IamHWE of 0 indicates a reduction
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to solely population-specific (not individual-specific) genomic information for a variant.
Iamchance/HWE of 1 indicates variants for which complete individual-specific genomic
information is available. hiQ of 0 indicates complete inter-individual homogeneity of
dosages across the sample. hiQ of 1 indicates that statistical tests can derive all their
power from heterogeneity between dosages.
However, it has been discussed that any imputation accuracy measures assuming
HWE to calculate "expected" genotype counts can be confounded. This was demonstrated for MaCH r2 [25]. For the proposed method, HWE is solely chosen as anchor
point to define pure population informative dosages. One should keep in mind that
Iam hiQ is just a tool for quality assurance and not a data analysis module. Thus, slight
violations from HWE do not compromise their use, but in case of family data caution is
advised. In such cases, one can either apply IamHWE to founders only, or use Iamchance.
Finally, accuracy measures with non-justified thresholds, as e.g. info, should be applied
with caution. This in mind, we derived thresholds for Iam hiQ, in contrast to other measures, from observation on a large sample and follow a traceable logic. Because its direct
and linear relationship to the average amount of individual-specific genomic information contained in the dosages of a marker, Iam is easy to interpret. By this, it differs from
r2, which is approximately equal to the power of the same test with r2N samples.
For the presented quality assurance, we calculated Iam hiQ for autosomes only.
Extending this to the X and Y chromosome is possible, but the sex of genotyped individual and the position of the variant on the chromosome must be taken into account
when calculating a correct HWE distribution. Even an ex post application of Iam hiQ
can be useful, particular to explain whether missed replication of an observed markerphenotype association is due to inaccurate imputation. Since the imputation accuracy of
particularly rare markers tend to be low, an improved imputation of the ILCCO samples
is planned on newer panels that contain more SNPS with low MAF.

Conclusion
In summary, Iam hiQ is a newly proposed pair of accuracy measures for imputed genotypes. In contrast to others, it addresses directly the contents of individual-specific
genotype information and the heterogeneity between dosages. It is independent of the
imputation platform and can be computed for all imputed variants. We recommend
using Iam hiQ additional to other accuracy scores for variation filtering before stepping
into the analysis of imputed GWAS data.
Availability of data and materials

A macro for SAS® 9.4 to calculate the measures IamHWE, Iamchance and hiQ for autosomal markers based on the dosage-file as output of IMPUTE2 is provided with the Additional file 1.
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Materials and methods
Novel accuracy measure

In the following we will consider m = 1 to M markers with two alleles (a and A) and
a MAF fA in the source population of the study sample consisting of N individuals.
The three possible genotypes aa, aA, and AA are indicated by allele doses 0, 1 and 2
(equal to the number of minor alleles A of a genotype). Imputation will result in tri

plets of a-posteriori genotype probabilities p0 p1 p2 , referred to as dosages, with
2
g=0 pg = 1. We assume the whole uncertainty related to genotype imputation is contained in these triplets. The allele dose of an individual i for an imputed marker will then

be di,m = 2i=0 i · pi and can take any value between 0 and 2. Multi-allelic markers are
assumed to be split into pseudo-two-allele variants.
Index of individual‑specific versus population‑specific genotype information: Iam

To quantify the amount of individual-specific versus population-specific genotype information in the dosages of the imputed single marker m for a single person i, we first consider the following three marginal situations:



(1) The triplet of dosages takes on the values 1 0 0 , or in a different order, if imputation is fully sufficient, when the missing genotype is unambiguously derived from
the reference panel. Thus, the dosages contain fully individual-specific genotype
information.
(2) In contrast, if all genotypes are equally likely the dosages take on the values


1/3 1/3 1/3 and imputing of the missing genotype failed (choosing a best guess
genotype would be completely due to chance). The dosages contain no individualspecific genotype information at all. 

 
 
(3) If the dosages take on the values fA2 2fA 1 − fA 1 − fA 2 and hence follow
HWE, imputation used solely MAF in the reference population and thus the dosages contain solely population-specific information.





an index to distinguish dosages 1 0 0 from 1/3 1/3 1/3 , or
 To construct

 
2
respectively, we were guided by the well-established HerfA2 2fA 1 − fA 1 − fA

findahl–Hirschman Index (HHI) [26]. HHI is a concentration measure for distribu
tions of discrete random variables with k possible realisations, defined as = ki=1 pk2 .
HHI ranges from 1 (if pj = 1 and pk =j = 0 ; alike (i)) to 1/k (if all pk = 1/k ; alike [ii]).
Because we are interested in anti-concentration, the opposite of HHI, we first define
the quantity.



Qi,m = 3g=1 pg,i,m 1 − pg,i,m for each marker m and each individual i. Qi,m takes




the value 0 in case of [i]: 1 0 0 and the value 2/3 in case of [ii]: 1/3 1/3 1/3 . To
achieve an imputation accuracy measure (Iam) for each marker m, we then rescaled
N

Qi,m to
the average across all individuals Qm = N1
i=1

Iamchance,m

Q
= 1− m.
2/3
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Iamchance ranges from 0 (in case of [ii]: non-informative dosages) to 1 (in case of [i]:
fully individual genotype information).


 
 
Similarly, Qm can be rescaled to represent situation [iii]: fA2 2fA 1 − fA 1 − fA 2
by the index value 0. In this case Qi,m takes the value

  

 

QHWE,m = fA2 1 − fA2 + 2fA 1 − fA 1 − 2fA 1 − fA


2 
2 
+ 1 − fA
1 − 1 − fA




= −2fA fA − 1 3fA2 − 3fA + 2

This alternative of the imputation accuracy measure (Iam) can be straightforwardly
calculated by

IamHWE,m = 1 −

Qm
QHWE,m

Figure 4 visually presents these definitions of Iam.
Iamchance = 0 indicates that the 3 genotypes are equally likely, averaged over all individuals. Therefore, imputation did not contribute any information at all.
IamHWE = 0 indicates that the genotypes are just as likely as under the HWE, averaged over all individuals. Therefore, imputation contributes only information of MAF in
the population (respectively the reference sample), but not for further individual-specific
information.
The computation of both Iam indices requires only the dosages provided by the imputation program used. For case–control or cross-sectional studies MAF can by estimated
by averaging the allele doses across all individuals, using the same data:

N
fˆA = i=1 d i,m 2N .

fˆA will be calculated fair enough for the outlined purpose even for markers that are
associated to a trait and therefore have different MAFs between affected and unaffected individuals. The same applies in the presence of low grade hidden relationships.

non-informative
dosages

population-informative
dosages

genetic information

fully informative
dosages

individual
HWE (given MAF)

0
0

population

1
1

Fig. 4 From dosages to Iam-indices. MAF/fA minor allele frequency; HWE Hardy–Weinberg equilibrium; Iam
imputation accuracy measure
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However, if the study sample consists of relatives, it is advisable to consider only unrelated founders for the estimation of fˆA.
QHWE,i,m depends on MAF. For rare markers QHWE,i,m is much closer to 0 than for
common markers (see Table 3). In case all dosages correspond to HWE (as in situation
[iii]) Iamchance for common markers is close to 0 (indicating inaccurate imputation),
whereas for rare markers it is close to 1 (misleadingly indicating accurate imputation).
This shows that it is fairly hard to determine the content of individual-specific information in the triplet of dosages of rare markers.
It is possible that IamHWE,i,m takes negative values, if the majority of triplets of dosages can be located between the non-informative and population-informative case. This
might be caused by genotyping errors as well as by small deviations between sample and
population MAF or locally increased inbreeding coefficients in the source population.
Some values of Qi,m will then be between 2/3 and QHWE,i,m. Due to the upper mentioned
shift of QHWE,i,m by MAF, this is more likely for rare than for common markers. However, small negative values should be regarded as occurred by pure chance.

Index of heterogeneity in quantities: hiQ

Inter-individual heterogeneity of dosages for a marker m is a second concern with
respect to the usability of imputed genotypes. Consider the following example: Table 4


gives two markers with average dosages 0.6 0.3 0.1 across 10 individuals. Marker 1
is not suitable for any data analysis, because all dosages are identical. The best guess for
all individuals is genotype aa. In contrast, marker 2 consists of three different dosages,
leading to different best guess genotypes for the individuals. This heterogeneity serves
power for statistical testing.
To construct an index of heterogeneity in quantities of dosages (hiQ) we compare
“average dosages”(ad) across all individuals with “average of best guess dosages” (ab)
applying the Hellinger H-distance. The H-distance quantifies the distance between two
(trinomial) probability distributions, taking value H = 0 in case of coincident probability
Table 3 Q and Iamchance by MAF
MAF

Qchance

QHWE

Iamchance
based on Q
 HWE

50%

0.667

0.625

0.0625

40%

0.667

0.614

0.0784

30%

0.667

0.575

0.1369

20%

0.667

0.486

0.2704

10%

0.667

0.311

0.5329

5%

0.667

0.176

0.7353

1%

0.667

0.039

0.9415

0.1%

0.667

0.0040

0.9940

0.01%

0.667

0.0004

0.9994

0.001%

0.667

0.00004

0.9999

0.0001%

0.667

0.000004
1.0000

minor allele frequency(fA), Qchance refers to a dosage of 1/3 1/3 1/3 ; QHWE refers to a dosage of
MAF:
fA2 2fA2 (1 − fA )2 1 − fA2
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distributions and H = 1 if the probability vectors are perpendicular [27, 28]. Therefore,
we defined


3 


   
hiQ = 1 − 1 −
fad g fbg g .
g=1

  

In Table 4 the “average of best guess dosages” for marker 1 fbg g =1 0 0 compared
√
  

to the average dosages ( fad g = 0.6 0.3 0.1 ) yields an hiQ = 1 − 1 − 0.6 = 0.53.
This indicates a loss of heterogeneity between dosages and reduced power of a statisti 
 
cal test. For marker 2, where fad g = fbg g , hiQ takes on the value 1, indicating fully
achievable inter-individual heterogeneity and no reduced power of a statistical test.
A SAS® macro far calculating IamHWE, Iamchance and hiQ based on the dosage-file as
output of IMPUTE2 is included in the Additional file 1.

Application to a sample of lung cancer patients and controls

We applied the novel indices to a dataset of the Integrative Analysis of Lung Cancer Etiology and Risk program of the International Lung Cancer Consortium (INTEGRALILCCO) to examine the behaviour of Iam hiQ, to find appropriate thresholds for marker
filtering and for comparison with an established accuracy measure. The sample comprises 14,803 lung cancer cases and 12,262 controls of European descent. They were genotyped on the OncoArray, which queried 517,482 SNPs. The array is designed to cover
the whole genome (with GWAS backbone) and for fine mapping of susceptibility to common cancers as well as for de novo discovery, and hence is enriched with low frequent
and rare variants [29]. About 50% of markers are considered as GWAS backbone. Details
of the sample, the genotyping and the quality control are given elsewhere [30]. The
OncoArray whole-genome data were imputed in a two-stage procedure, using SHAPEIT
to derive phased genotypes and IMPUTEv2 to infer additional genotypes for genetic
variants included in the 1000 Genomes Project (phase 3 panel) [6, 15]. We restricted calculations and comparisons to markers of the autosomes. A total of n = 10,427,599 SNPs

Table 4 Inter-individual heterogeneity of dosages: example
ID

Marker 1
aa

Marker 2
aA

AA

aa

aA

AA

1

0.6

0.3

0.1

1

0

0

2

0.6

0.3

0.1

1

0

0

3

0.6

0.3

0.1

1

0

0

4

0.6

0.3

0.1

1

0

0

5

0.6

0.3

0.1

1

0

0

6

0.6

0.3

0.1

1

0

0

7

0.6

0.3

0.1

0

1

0

8

0.6

0.3

0.1

0

1

0

9

0.6

0.3

0.1

0

1

0

10

0.6

0.3

0.1

0

0

1

Avg

0.6

0.3

0.1

0.6

0.3

0.1
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were finally included in this quality assessment. Presumably difficult to impute, due to
their MAF, are 5,226,623 of these SNPs (50%) with a MAF lower than 1% and 1,500,835
SNPs with a MAF between 1 and 5% (Additional file 2).
Abbreviations
Iam:: Imputation accuracy measure; hiQ:: Heterogeneity in quantities of dosages; ILCCO:: International Lung Cancer Consortium; SNP:: Single nucleotide polymorphism; SV:: Structural variation; GWAS:: Genome-wide association studies; MAF::
Minor allele frequency; HWE:: Hardy–Weinberg disequilibrium.
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